Table 1.

Discussion questions.

Domain	Questions
Treatment decision-making and preferences	•When making decisions about treatment, what aspects of treatment do patients with mBC most value or factor into their deliberations and why? •How can patient-physician dialogue be improved regarding treatment options and alignment around treatment goals? •After a treatment has been started, in what ways do patients with mBC evaluate response to treatment?
Treatment-related quality of life	•What does quality of life (QoL) mean for patients with mBC? •Which aspects of treatment can strongly impact on QoL for patients with mBC? •How important is mode of treatment administration for patients with mBC?
Perspectives on PFS terminology	•How do patients view the period of time during or after treatment when their cancer is not growing or spreading? •“Progression-free survival” and “stable” disease are clinical terms used by doctors and researchers. Do you think patients understand these terms? •What other terms may better capture this concept for patients with mBC?
Productivity impacts and financial toxicity	•How do patients with mBC account for potential impacts to work-related productivity and financial considerations when deliberating treatment options and making treatment decisions? •How do financial issues shape treatment preferences and decision-making? •Are these issues being addressed as part of the patient-provider dialogue? Why or why not?
Caregiver burden	•How do patients with mBC take into account the impact of a therapy on their caregivers at different points in the treatment journey? •In what ways are caregivers involved and influence treatment decision-making? •Are there other impacts on caregivers that are not reflected in the summary?